Request for permission for oral testimony at Idaho Medicaid's P&T Committee meeting on 04-15-2011

Submission # 4

The following request has been:

- o Approved
- X Denied

Gennrich, Jane - Medicaid

From: Eide, Tamara J. - Medicaid
Sent: Monday, March 14, 2011 4:22 PM
To: Gennrich, Jane - Medicaid
Subject: FW: Request for Oral Testimony
Attachments: Idaho medicaid P&TLovaza.docx

Tami Eide, Pharm.D., BCPS
Medicaid Pharmacy Program Supervisor/Manager
Idaho Department of Health and Welfare
eidet@dhw.idaho.gov
3232 Elder St.
Boise, ID 83705
208-364-1829
800-327-5541 fax

From: Linda Dawson [mailto:linda.j.dawson@gsk.com]
Sent: Monday, March 14, 2011 1:46 PM
To: Eide, Tamara J. - Medicaid
Subject: Request for Oral Testimony

Greetings Tami,

Attached is a request for an opportunity to speak on new information about *Lovaza* at your upcoming P&T Medicaid meeting.

Regards, Linda

Linda J. Dawson, Pharm.D., MPH, CPH
Sr. Medical Information Scientist II
GlaxoSmithKline
Medical Information Department
T (919) 483-4177
Fax (919) 315-3081
email: linda.j.dawson@gsk.com
http://www.gsk.com

March 10, 2011

Tami Eide, Pharm.D.
eidet@dhw.idaho.gov

Dear Idaho P&T Committee:

Based on the submission guidelines for the public comment process, I would like to request that I be allowed to present information on *Lovaza* (omega-3-acid-ethyl esters) at your upcoming April 15th 2011 Idaho Medicaid P&T review meeting.

- Based on a recent FDA assessment of causality, multiple adverse reactions were removed from the prescribing information for *Lovaza*.

Thank you in advance for your consideration of my request.

Sincerely,

Brian F. Streng, Pharm.D., MBA
Medical Liaison
North American Medical Affairs
GlaxoSmithKline
480-250-3832 (Office / Cell)